Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Hedge Fund Third Point Urges Amgen to Consider Breakup

By Pharmaceutical Processing | October 22, 2014

A hedge fund run by a famed investor said Tuesday it has taken a large stake in Amgen and now wants the biotech drugmaker to consider splitting up into two.

In a letter to investors, Third Point, a hedge fund run by Daniel Loeb, said it has recently increased its stake by an unspecified amount, making it one of the drugmaker’s top shareholders. According to FactSet, Third Point already owned about 450,000 Amgen shares, a stake worth roughly $64.8 million.

In response, Amgen said that its board and management are continually assessing the company’s business.

Third Point said Amgen Inc., which makes a range of drugs for arthritis, anemia and other diseases, is not given enough credit for its existing drugs or the potential of its pipeline. It believes that the stock can reach $218 by the end of 2016 — up 51 percent from Tuesday’s close — if Amgen focused on research and development and trimmed expenses. Should the company pursue its suggestion to breaking up into two companies, Third Point said it believes that the total value would be nearly $249 per share.

Amgen, based in Thousand Oaks, California, said it will update investors about its restructuring when it reports results next week. In its last quarterly report it announced it would lay off up to 15 percent of its workforce and shut four sites.

Shares of Amgen are up about 26 percent in the year to date, versus a 5 percent gain in the benchmark S&P 500 index.

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE